---
figid: PMC5712254__nihms915140f1
figtitle: Metabolic Advantages and Vulnerabilities in Brain Metastases
organisms:
- NA
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC5712254
filename: nihms915140f1.jpg
figlink: /pmc/articles/PMC5712254/figure/F1/
number: F1
caption: 'A) Amplification of EGFR activates mTORC2, AKT, and c-Myc to promote metabolic
  reprogramming. EGFR variant III is shown as a representative mutation causing EGFR
  activation because it is commonly found in glioblastoma and breast cancer (, ).
  B) AKT and c-Myc (in green) activate enzymes (in blue) involved in glycolysis, the
  pentose phosphate pathway, and glutamine catabolism to supply energy and macromolecules
  to rapidly proliferating cancer cells.Reprinted by permission from Elsevier: Cell
  Press, copyright 2014.Masui K, Cavenee WK, Mischel PS. (2014) mTORC2 in the center
  of cancer metabolic reprogramming. Trends in endocrinology and metabolism: TEM.
  25: 364–73. PMID: 24856037; PMCID: PMC4077930'
papertitle: Metabolic Advantages and Vulnerabilities in Brain Metastases.
reftext: Alexandra K. Ciminera, et al. Clin Exp Metastasis. ;34(6-7):401-410.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9248725
figid_alias: PMC5712254__F1
figtype: Figure
redirect_from: /figures/PMC5712254__F1
ndex: 72d20785-df0c-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5712254__nihms915140f1.html
  '@type': Dataset
  description: 'A) Amplification of EGFR activates mTORC2, AKT, and c-Myc to promote
    metabolic reprogramming. EGFR variant III is shown as a representative mutation
    causing EGFR activation because it is commonly found in glioblastoma and breast
    cancer (, ). B) AKT and c-Myc (in green) activate enzymes (in blue) involved in
    glycolysis, the pentose phosphate pathway, and glutamine catabolism to supply
    energy and macromolecules to rapidly proliferating cancer cells.Reprinted by permission
    from Elsevier: Cell Press, copyright 2014.Masui K, Cavenee WK, Mischel PS. (2014)
    mTORC2 in the center of cancer metabolic reprogramming. Trends in endocrinology
    and metabolism: TEM. 25: 364–73. PMID: 24856037; PMCID: PMC4077930'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HK2
  - KCNA5
  - KIF2A
  - KLK2
  - HOOK2
  - PGD
  - PHGDH
  - G6PD
  - UBL4A
  - PFKP
  - TALDO1
  - RPIA
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - MYC
  - PDK1
  - PDPK1
  - PKM
  - PKLR
  - GNAS
  - AKT1
  - AKT2
  - AKT3
  - GLS
  - GLS2
  - hk2
  - pgd
  - g6pd
  - taldo1
  - rpia
  - phgdh
  - rictorb
  - mtor
  - myca
  - pdk1
  - pkma
  - dharma
  - glsb
  - 3-Phosphoglycerate
  - 6-Phosphogluconate
  - Ribulose-5-P
  - Fructose-1,6-BP
  - Fructose-6-P
  - Fumarate
  - Glucose
  - Glucose-6-P
  - Glutamine
  - Glyceraldehyde-3-P
  - Isocitrate
  - lactone
  - Oxaloacetate
  - phosphate
  - Phosphoenolpyruvate
  - Pyruvate
  - Ribose-5-P
  - Serine
  - Succinate
  - Glutamate
  - Lactate
---
